Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Arbaclofen - Seaside Therapeutics

Drug Profile

Arbaclofen - Seaside Therapeutics

Alternative Names: R-baclofen; STX-209

Latest Information Update: 20 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Seaside Therapeutics
  • Developer Seaside Therapeutics; The Childrens Hospital of Philadelphia; UMC
  • Class Aminobutyric acids; Behavioural disorder therapies; Gastrokinetics; Muscle relaxants; Small molecules
  • Mechanism of Action GABA B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Fragile X syndrome
  • Phase II Autistic disorder

Most Recent Events

  • 18 Sep 2023 Allos Pharma has patent protection for arbaclofen in USA
  • 18 Sep 2023 Allos Pharma plans a confirmatory phase III trial in Fragile X syndrome
  • 23 May 2023 Arbaclofen is still in phase III trials for Fragile X syndrome (In adolescents, In adults) in USA (PO, fast dissolve tablet)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top